Suzanne Wollen-Roberts

Mrs. Suzanne Wollen-Roberts

US Military HIV Research Program (MHRP) and Emerging Infectious Diseases (EID) Branch, Walter Reed Army Institute of Research (WRAIR)
orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 March 2016 in Science
Verified
Journal Article
Closed access
PDF file
DCDavide Corti
Davide Corti
JMJohn Misasi
John Misasi
SMSabue Mulangu
Sabue Mulangu
DSDaphne A. Stanley
Daphne A. Stanley
MKMasaru Kanekiyo
Masaru Kanekiyo
Nancy J. SullivanNancy J. Sullivan
Nancy J. Sullivan
Antibodies block Ebola virus entry: The recent Ebola virus outbreak in West Africa illustrates the need for both an effective vaccine and therapies to treat infected individuals. Corti et al. isolated two monoclonal antibodies from a survivor of the 1995 Kikwit outbreak and demonstrated their therapeutic efficacy in Ebola virus–infected macaques. In fact, one antibody protected macaques when it was given up to 5 days after infection. Misasi et al. solved the crystal structures of fragments of the two antibodies bound to the Ebola virus glycoprotein (GP), which mediates viral cell entry. The two antibodies targeted different regions of GP, but in both cases blocked steps required for viral entry. Science , this issue pp. 1339 & 1343

4 March 2016 in Science
Verified
Journal Article
Closed access
PDF file
ZBZachary A. Bornholdt
Zachary A. Bornholdt
HTHannah L. Turner
Hannah L. Turner
CMCharles D. Murin
Charles D. Murin
WLWen Li
Wen Li
DSDevin Sok
Devin Sok
LWLaura M. Walker
Laura M. Walker
Profiling the antibody response to Ebola: The recent Ebola virus outbreak in West Africa illustrates the need not only for a vaccine but for potential therapies, too. One promising therapy is monoclonal antibodies that target Ebola's membrane-anchored glycoprotein (GP). Bornholdt et al. isolated and characterized 349 antibodies from a survivor of the 2014 outbreak. A large fraction showed some neutralizing activity and several were quite potent. Structural analysis revealed an important site of vulnerability on the membrane stalk region of GP. Antibodies targeting this area were therapeutically effective in Ebola virus–infected mice. Science , this issue p. 1078

31 May 2018 in The Journal of Infectious Diseases
Verified
Journal Article
Open access
PDF file
KPKristen E Pascal
Kristen E Pascal
DDDrew Dudgeon
Drew Dudgeon
JTJohn C Trefry
John C Trefry
MAManu Anantpadma
Manu Anantpadma
YSYasuteru Sakurai
Yasuteru Sakurai
CKChristos A Kyratsous
Christos A Kyratsous
For most classes of drugs, rapid development of therapeutics to treat emerging infections is challenged by the timelines needed to identify compounds with the desired efficacy, safety, and pharmacokinetic profiles. Fully human monoclonal antibodies (mAbs) provide an attractive method to overcome many of these hurdles to rapidly produce therapeutics for emerging diseases. In this study, we deployed a platform to generate, test, and develop fully human antibodies to Zaire ebolavirus. We obtained specific anti-Ebola virus (EBOV) antibodies by immunizing VelocImmune mice that use human immunoglobulin variable regions in their humoral responses. Of the antibody clones isolated, 3 were selected as best at neutralizing EBOV and triggering FcγRIIIa. Binding studies and negative-stain electron microscopy revealed that the 3 selected antibodies bind to non-overlapping epitopes, including a potentially new protective epitope not targeted by other antibody-based treatments. When combined, a single dose of a cocktail of the 3 antibodies protected nonhuman primates (NHPs) from EBOV disease even after disease symptoms were apparent. This antibody cocktail provides complementary mechanisms of actions, incorporates novel specificities, and demonstrates high-level postexposure protection from lethal EBOV disease in NHPs. It is now undergoing testing in normal healthy volunteers in preparation for potential use in future Ebola epidemics.

21 September 2017 in Human Vaccines & Immunotherapeutics
Verified
Journal Article
Open access
KCKathleen Cashman
Kathleen Cashman
EWEric R. Wilkinson
Eric R. Wilkinson
CSCarl I Shaia
Carl I Shaia
PFPaul R. Facemire
Paul R. Facemire
TBTodd M. Bell
Todd M. Bell
CSConnie S. Schmaljohn
Connie S. Schmaljohn
Lassa virus (LASV) is an ambisense RNA virus in the Arenaviridae family and is the etiological agent of Lassa fever, a severe hemorrhagic disease endemic to West and Central Africa. 1,2 Buchmeier MJ , De La Torre JC , Peters CJ . Arenaviridae: The viruses and their replication. In: Knipe DM , Howley PM , Griffin DE , Lamb RA , Martin A , Roizman B , et al., editors. Fields virology.. New York : Lippincott, Williams & Wilkins; 2007:1792-827. Enria DA , Mills JN , Bausch DG , Shieh WJ , Peters CJ . Arenavirus infections. In: Guerrant RL , Walker DH , Weller PF , editors. Tropical infectious diseases: Principles, pathogens & practice.. New York : Elsevier; 2011. p. 1130. There are no US Food and Drug Administration (FDA)-licensed vaccines available to prevent Lassa fever. 1,2 Buchmeier MJ , De La Torre JC , Peters CJ . Arenaviridae: The viruses and their replication. In: Knipe DM , Howley PM , Griffin DE , Lamb RA , Martin A , Roizman B , et al., editors. Fields virology.. New York : Lippincott, Williams & Wilkins; 2007:1792-827. Enria DA , Mills JN , Bausch DG , Shieh WJ , Peters CJ . Arenavirus infections. In: Guerrant RL , Walker DH , Weller PF , editors. Tropical infectious diseases: Principles, pathogens & practice.. New York : Elsevier; 2011. p. 1130. in our previous studies, we developed a gene-optimized DNA vaccine that encodes the glycoprotein precursor gene of LASV (Josiah strain) and demonstrated that 3 vaccinations accompanied by dermal electroporation protected guinea pigs from LASV-associated illness and death. Here, we describe an initial efficacy experiment in cynomolgus macaque nonhuman primates (NHPs) in which we followed an identical 3-dose vaccine schedule that was successful in guinea pigs, and a follow-on experiment in which we used an accelerated vaccination strategy consisting of 2 administrations, spaced 4 weeks apart. In both studies, all of the LASV DNA-vaccinated NHPs survived challenge and none of them had measureable, sustained viremia or displayed weight loss or other disease signs post-exposure. Three of 10 mock-vaccinates survived exposure to LASV, but all of them became acutely ill post-exposure and remained chronically ill to the study end point (45 d post-exposure). Two of the 3 survivors experienced sensorineural hearing loss (described elsewhere). These results clearly demonstrate that the LASV DNA vaccine combined with dermal electroporation is a highly effective candidate for eventual use in humans.

1 August 2017 in Emerging Infectious Diseases
Verified
Journal Article
Open access
AHAndrew Haddow
Andrew Haddow
ANAysegul Nalca
Aysegul Nalca
FRFranco D Rossi
Franco D Rossi
LMLynn J Miller
Lynn J Miller
MWMichael Wiley
Michael Wiley
FNFarooq Nasar
Farooq Nasar
Unprotected sexual intercourse between persons residing in or traveling from regions with Zika virus transmission is a risk factor for infection. To model risk for infection after sexual intercourse, we inoculated rhesus and cynomolgus macaques with Zika virus by intravaginal or intrarectal routes. In macaques inoculated intravaginally, we detected viremia and virus RNA in 50% of macaques, followed by seroconversion. In macaques inoculated intrarectally, we detected viremia, virus RNA, or both, in 100% of both species, followed by seroconversion. The magnitude and duration of infectious virus in the blood of macaques suggest humans infected with Zika virus through sexual transmission will likely generate viremias sufficient to infect competent mosquito vectors. Our results indicate that transmission of Zika virus by sexual intercourse might serve as a virus maintenance mechanism in the absence of mosquito-to-human transmission and could increase the probability of establishment and spread of Zika virus in regions where this virus is not present.

21 June 2018 in PLOS Neglected Tropical Diseases
Verified
Journal Article
Open access
PDF file
EMEric M Mucker
Eric M Mucker
SWSuzanne Wollen-Roberts
Suzanne Wollen-Roberts
AKAdrienne Kimmel
Adrienne Kimmel
JSJosh Shamblin
Josh Shamblin
DSDarryl Sampey
Darryl Sampey
JHJay Hooper
Jay Hooper
Concerns regarding outbreaks of human monkeypox or the potential reintroduction of smallpox into an immunological naïve population have prompted the development of animal models and countermeasures. Here we present a marmoset model of monkeypox and smallpox disease utilizing a relevant poxvirus via a natural exposure route. We found that 1000 plaque forming units (PFU) of Monkeypox virus was sufficient to recapitulate smallpox disease, to include an incubation period of approximately 13 days, followed by the onset of rash, and death between 15 and 17 days. Temporally accurate manifestation of viremia and oral shedding were also features. The number of lesions ranged from no lesions to 299, the most reported in a marmoset exposed to a poxvirus. To both evaluate the efficacy of our antibodies and the applicability of the model system, marmosets were prophylactically treated with two monoclonal antibodies, c7D11 and c8A. Of three marmosets, two were completely free of disease and a single marmoset died 8 days after the mock (n = 1) or PBS control(s) (n = 2). Evaluation of the serum levels of the three animals provided a possible explanation to the animal succumbing to disease. Interestingly, more females had lesions (and a greater number of lesions) and lower viral burden (viremia and oral shedding) than males in our studies, suggesting a possible gender effect. Poxviruses are large viruses capable of causing disease in humans. Of the known poxviruses, variola virus and monkeypox virus cause the most severe disease, smallpox and human monkeypox, respectively. Models utilizing these viruses are valuable for the study of host-virus interaction and for evaluating countermeasures. Arguably the best models utilizing variola virus or monkeypox virus involve the intravenous inoculation of nonhuman primates. Because these models have an unnatural route of infection and bypass the incubation of the disease, more genuine models are sought. Here we tested whether marmosets could be infected with monkeypox virus via a natural route and, if so, whether the model could be applied to study countermeasures. We found that the animals were susceptible to monekypox virus at a low dose via a natural route, uncannily mirrored human disease onset, and could be protected by prophylactic treatment of two novel monoclonal antibodies. Furthermore, we found potential disease disparity between males and females that, if proven true, could stimulate the exploration of a mechanistic explanation to describe the disparity and deepen our understanding of poxvirus pathogenesis, immunology and/or marmoset biology.